We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease

By LabMedica International staff writers
Posted on 25 Jun 2026

Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. More...

This gap has limited sex-specific diagnostic and prognostic tools. A new study now identifies a female-specific chimeric RNA that influences blood cell development and is associated with COVID-19 severity.

At the University of Virginia (UVA) School of Medicine, investigators identified UBA1-CDK16, a chimeric RNA found only in women. Chimeric RNAs are molecules assembled from parts of different genes rather than a single locus. UBA1-CDK16 originates from the inactive X chromosome and can be detected in women’s blood.

The team linked UBA1-CDK16 to hematopoiesis and immune regulation in women. The RNA’s female specificity reflects X-chromosome biology, with the inactive X producing this sequence despite global silencing. The authors highlight that chimeric RNAs, once regarded as cancer byproducts, can also be part of normal physiology with regulatory functions.

Findings reported that UBA1-CDK16 was absent in 50% of women who developed severe COVID-19, while it remained present in women who were asymptomatic. Lower levels of the RNA tracked with increasing infection severity. The researchers also suggest a role in governing neutrophil development, consistent with known links between neutrophil counts and COVID-19 outcomes.

The work appears in Science Advances on May 29, 2026. The study was conducted in UVA’s Department of Pathology in collaboration with the UVA Comprehensive Cancer Center. The authors add that UBA1-CDK16 may act as a natural brake on excessive autoimmune activity in women and could inform development of blood-based tests to diagnose disease or stratify risk, pending additional research.

“Chimeric RNAs are RNA molecules composed of parts from different genes. They were once believed to be cancer-specific. However, our research shows that they can also be part of normal physiology and play important roles in human health,” said Hui Li, Ph.D., of the Department of Pathology and the UVA Comprehensive Cancer Center, University of Virginia.

"This finding highlights that there is another layer of control for gene expression. These chimeric RNAs may represent a hidden repertoire for biomarkers and therapy targets as well," said Li.

Related Links
UVA School of Medicine


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.